These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 3910330)

  • 1. [Clinical study of 42 patients treated with ceftazidime].
    Farci G; Laconi R; Lai ME; Balestrieri A
    Clin Ter; 1985 Nov; 115(3):169-72. PubMed ID: 3910330
    [No Abstract]   [Full Text] [Related]  

  • 2. Ceftazidime in febrile SLE patients.
    Boey ML; Feng PH
    Singapore Med J; 1988 Aug; 29(4):393-5. PubMed ID: 3074518
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment with ceftazidime of difficult and severe (hospital and non-hospital) infections].
    Sueri L; Scalzini A; Barni C; Chiodera A
    G Ital Chemioter; 1985; 32(2):399-402. PubMed ID: 3914431
    [No Abstract]   [Full Text] [Related]  

  • 4. Ceftazidime in the treatment of acute severe infections in children and adults.
    Păun L; Ceauşu E
    Arch Roum Pathol Exp Microbiol; 1989; 48(2):177-84. PubMed ID: 2699410
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of ceftazidime in the treatment of osteomyelitis and osteoarthritis.
    De Bastiani G; Nogarin L; Molinaroli F; Bragantini A; Fostini R
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):677-9. PubMed ID: 3546169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of a new beta-lactam antibiotic, ceftazidime, in the neurosurgical intensive care unit. Preliminary observations].
    Ravelli V; Buonaguidi R; Lutzemberger L
    Minerva Anestesiol; 1985 Sep; 51(9):471-3. PubMed ID: 3913880
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ceftazidime in the treatment of bacterial meningitis].
    Duniewicz M; Stanková M; Absolonová V; Havlík J; Potuzník V; Lochmann O
    Sb Lek; 1988 Oct; 90(10):318-22. PubMed ID: 3060978
    [No Abstract]   [Full Text] [Related]  

  • 8. Topical use of ceftazidime in gram negative pulmonary pathologies.
    Barberis S; Cristaldi G; Galietti F; Giorgis GE; Massaglia GM
    Panminerva Med; 1985; 27(4):189-94. PubMed ID: 3913889
    [No Abstract]   [Full Text] [Related]  

  • 9. [Ceftazidime in the treatment of severe bacterial infections].
    Maresová V; Cizmárová L; Havlík J; Stafová J; Vacek V; Gabrielová A; Neubertová K
    Sb Lek; 1988 Nov; 90(11-12):339-43. PubMed ID: 3064274
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ceftazidime in the treatment of infections in intensive care. Experience with 20 clinical cases].
    Liverta E; Pasquetti G; Carnevali M; Bellucci MC
    Minerva Anestesiol; 1986; 52(1-2):47-9. PubMed ID: 3526183
    [No Abstract]   [Full Text] [Related]  

  • 12. Position of ceftazidime in respiratory diseases.
    Ando' F; Girbino G; Ferrara F
    Drugs Exp Clin Res; 1985; 11(6):369-72. PubMed ID: 3915288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with ceftazidime in the management of a variety of gram-negative infections.
    Spantideas A
    Chemioterapia; 1987 Jun; 6(2 Suppl):377-8. PubMed ID: 3334580
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomised dosage study of ceftazidime with single daily tobramycin for the empirical management of febrile neutropenia in patients with hematological diseases.
    Gibson J; Johnson L; Snowdon L; Joshua D; Young G; MacLeod C; Iland H; Vincent P; Kronenberg H
    Int J Hematol; 1994 Aug; 60(2):119-27. PubMed ID: 7948961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic antimicrobial therapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime.
    Parish LC; Jungkind DL
    Am J Med; 1993 Mar; 94(3A):166S-173S. PubMed ID: 8452175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
    Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
    Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of ceftazidime in the treatment of severe localized and systemic infections.
    Gabrielli GB; Corrocher R; De Sandre G
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):167-9. PubMed ID: 6370875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical results of Fortum and Zinacef trial in Burn Centers of Russia].
    Alekseev AA; Krutikov MG; Smirnov SV; Malakhov SF; Filimonov AA
    Khirurgiia (Mosk); 1996; (5):55-9. PubMed ID: 9011659
    [No Abstract]   [Full Text] [Related]  

  • 19. [Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage].
    Cazzola M; Noschese P; Vinciguerra A; Di Perna F; Califano C; Berra A
    Minerva Med; 1998; 89(1-2):15-22. PubMed ID: 9561021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical assay of ceftazidime levels in tissues of the relatively ischaemic limb.
    Smith RM; Stewart J; Kester RC; Ramsden CH
    Br J Clin Pract; 1985 Mar; 39(3):94-7. PubMed ID: 3885991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.